Member Info for avctIPmatters

Reducing principal amount £25.5 million. Not really a big amount . Might attract a biotech fund to do an escrow type deal after all the goal of the company remains . --- "advance the Company's R&D pipeline and value creation opportunities "

Today RNS not unexpected future looks very bright for the science - AACR posters coming up keep the faith if you can .

Have a nice day

gmcc

Session PO.CT01.02 - First-in-Human Phase I Clinical Trials 2

CT151 / 17 - Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates

Abstract

"Abstract is embargoed at this time."

https://www.abstractsonline.com/pp8/#!/20273/presentation/10472

gmcc

According to https://www.morningstar.com/stocks/xlon/avct/ownership

Last AVCT tranche BG sold was -255,119 100.00% -255,119

So not a big deal - other owners listed still hold --swings & roundabouts - better to concentrate on what lies ahead IMO

Good luck gmcc .

BG - Suspect underwhelming stock price is the reason . BG have been reducing their stake over a period -

Likely reason "guidelines at the end of 2024 which include a reduction in the overall number of holdings. "

So Avacta fall into that catergory .

Avatca goal will be to attract new institutional biotech investors who see merit in "pre|CISION® platform " + major biotech partner/licence interest .in the delivery system.

Inflection points coming up should be well worth the wait IMO

gmcc

Good Morning

Note : some patent action from AffyXell Therapeutics

Courtesy https://x.com/hashtag/AVCT?src=hashtag_click&f=live

---------------

Patent pending application cites Avacta affimers

"Application KR1020240130803A events

2024-09-26

Application filed by 주식회사 아피셀테라퓨틱스

2025-04-04

Publication of KR20250047619A

Status

Pending"

https://patents.google.com/patent/KR20250047619A/en#relatedApplications

gmcc

" What is ipilimumab used for?

Ipilimumab is used to treat certain types of cancer, including

melanoma (skin cancer)

kidney cancer (renal cell carcinoma)

colon or rectal cancer (colorectal cancer)

liver cancer (hepatocellular carcinoma)

non-small cell lung cancer (NSCLC)

cancer of the lining of the lungs and chest wall (pleural mesothelioma)

squamous cell cancer of the esophagus

Ipilimumab is only used in certain circumstances, depending on what type of cancer you have, whether it has spread to other parts of your body, what other treatments you have tried, and for some cancers, it will depend on genetic markers."

Ipilimumab : Might be might be a possible candidate for Avacta pipeline AVA7100 program .

"Attachment of an Fc domain to a drug molecule is a modification used to extend the half-life of a number of approved drugs such as Enbrel®, Eylea® and Ultomiris®.[1] [2] Third Generation pre|CISION® Peptide Drug Conjugate"

https://avacta.com/our-science/3rd-gen-affdc/

https://link.springer.com/article/10.1007/s40259-015-0133-6/tables/5

https://avacta.com/pipeline/

Anyway no expert so perhaps not .

gmcc

No doubt in my mind that Avacta have a winner with their delivery preCISION® technology - which can be used /coupled with already approved proven cancer drugs - will provide safer treatment for cancer patients .

Beyond me why some folks here continually rubbish the company , will be a win/win for everyone involved .

-----------------

"Results – Our findings reveal high FAP expression across a range of tumor indications and demonstrate a correlation with novel biomarkers of interest. IHC analysis confirms a direct relationship between FAP RNA and protein expression, while multi-IF imaging and concentric partitioning analysis for a range of solid tumor indications shows the spatial association of tumor cells, blood vessels and CAFs expressing FAP. ScRNA-seq data confirms high level FAP expression on fibroblasts in stromal-rich tumors. Finally, co-culture models were established with tumor cells and matched fibroblasts which represent tumors with differing levels of FAP enzyme activity. Avacta’s preCISION® peptide-drug conjugates elicit bystander cell kill over a range of physiological FAP levels within these co-culture models.

Conclusions – Combined, these analyses emphasize the significance of FAP as an important stromal target for focused delivery of targeted oncology therapeutics, and guide further development of the preCISION® pipeline."

gmcc

FYI Note - Highlight Avacta AACR presentation : Nice coverage of abstract details :

"Investigating Fibroblast Activation Protein Alpha (FAPα) as a Therapeutic Target for Delivery of Pre|CISION® Cancer Medicines: Expression, Spatial Localization and Functional Insights"

https://www.tempus.com/publications/investigating-fibroblast-activation-protein-alpha-fap%ce%b1-as-a-therapeutic-target-for-delivery-of-precision-cancer-medicines-expression-spatial-localization-and-functional-insights/

https://tinyurl.com/2xb5ptz7

https://www.tempus.com/

gmcc

Coris : New video : ( still as far i know still part of Avacta )

"ReSCape - How to use product presentation

Coris BioConcept

226 subscribers

Subscribe

0

Share

10 views 14 Apr 2025 BELGIQUE

ReSCape - Culture reagents kit for C-PGNB on rectal swab for the detection of carbapenemases.

Compatible for all the targets of our RESIST kits (CTX-M & OXA-23 in validation).

Discover step by step how to use this additional kit with this product presentation video, which will give you useful indications on how to obtain accurate results."

https://www.youtube.com/watch?v=7BaPvItTX1E

gmcc

+ " The tumour microenvironment is intricately complex, conditioning stromal cells to support cancer cell viability, proliferation, and resistance to anti-cancer immunotherapies. Understanding the molecular underpinnings of these processes is crucial for identifying promising targets for pharmacological inhibition. We offer in vitro assays that faithfully recapitulate cancer pathology, aiding in holistic research."

https://www.conceptlifesciences.com/services/therapeutic-areas/immuno-oncology

Might be of interest : Note Avacta using external 2D/3D imaging assay services : Giulia Tagliavini Concept Life Sciences, Edinburgh, United Kingdom : listed on poster : .

"2699 / 16 - Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights"

https://www.conceptlifesciences.com/services/therapeutic-areas/oncology

_______________

Precision Oncology Insights for Effective Therapies

Therapeutic Areas

Oncology

Cancer is a complex, multifaceted disease with an array of traits or “hallmarks” that can be targeted by different therapeutic approaches. Our skilled team has extensive experience supporting companies in characterizing lead compounds through in vitro pharmacology. We're dedicated to delivering both established and customized assays, along with assay development services. Our testing platforms cover diverse 2D and 3D models, incorporating advanced techniques like molecular biology, high-content imaging, and live cell imaging."

gmcc

Abstracts

3139 / 24 - The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage

https://tinyurl.com/mrdrhcmr

2699 / 16 - Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights

https://tinyurl.com/4u34ejr7

Courtesy of Stonks X : https://x.com/JStonker/status/1911902781197139989

Avacta Life Sciences mentioned in this report , just one of many companies operating in this field ;

"Metastatic Prostate Cancer Pipeline 2025:"

However as @ bootnk19222 comment : Avacta have a better solution to this problem with current treatments .

"Metastatic Prostate Cancer Pipeline Market Barriers

• However, High Cost of Drug Development, Complex Disease Mechanism, Regulatory Hurdles, Adverse Side Effects of Treatments, and other factors are creating obstacles in the Metastatic Prostate Cancer Market growth."

https://www.openpr.com/news/3970526/metastatic-prostate-cancer-pipeline-2025-moa-roa

Just a matter of time IMO before major biotech interest in our little company - keep the faith --. be better for clinicians /patients & of course AVCT shareholders .

gmcc

FYI Last Update Posted 2025-04-13

https://clinicaltrials.gov/study/NCT04969835?tab=history&a=8&b=9#version-content-panel

----------

Patients with high grade soft tissue sarcoma or salivary gland cancer must not have previously received an anthracycline-based therapy.

Patients with TNBC may receive up to 250mg/m2 of prior doxorubicin (or an equivalent anthracycline). Prior anthracycline based therapy must have been completed at least 6 months before the planned Cycle 1 Day 1 AVA6000 infusion. Prior anthracycline use must have been in the adjuvant or neoadjuvant setting only.

Patients must provide at least 1 tissue sample collection, either archival or fresh tissue (approximately 10 slides) unless the biopsy is medically not able to be performed or the principal investigator deems it is not medically feasible.!

gmcc

Nice little video Coris stand busy product billboard -- Seems a niche market - be intersting to see what eventually happens .

-

https://www.corisbio.com/pdf/Products/General-product-catalogue.pdf

Antimicrobial Susceptibility Testing (AST)

Market Value (2024) US$ 3.9 billion

Forecast Revenue (2034) US$ 7.4 billion

https://market.us/report/global-antimicrobial-susceptibility-testing-market/

------------------

Linkedin :

"CORIS BIOCONCEPTCORIS BIOCONCEPT

2,856 followers2,856 followers

4h • 4 hours ago

https://www.linkedin.com/company/coris-bioconcept/posts/

https://www.corisbio.com/

Follow

hashtag#ESCMIDGlobal2025 - Messe Vienna

👉Follow us (literally!) to our booth H44!💥

hashtag#BehindTheScenes hashtag#ESCMID hashtag#Vienna hashtag#CorisBioConcept hashtag#AMR

------------

gmcc

LeakBot obviously better than current device promoted by Hanover :

https://www.hanover.com/individuals/customer-resources/proactive-protection-against-water-damage

FYI https://www.hanover.com/2023-home-water-damage-prevention-report

Https://www.hanover.com/

Craig Foster

@foster_ideas

🚨 Excited to welcome The Hanover as our latest US partner - Another Top 20 home insurer choosing LeakBot to prevent water damage for their customers.

Proud of the team and the growing momentum across the US. Onwards! 🇺🇸💧

#LeakBot #ONDO #InsurTech

gmcc

Https://x.com/foster_ideas/status/1910635548902883504

Craig Foster

@foster_ideas

Proud of what the team has delivered - if frustrated by some short-term timing delays, but:

LeakBot is now live with 7 US insurers, including 3 of the Top 20, covering almost 6 million homes across 23 states. 🇺🇸Customers up +435%

Real momentum in the right market. Big year ahead.

#ONDO #LeakBot #InsurTech